Search

Displaying results 1391 - 1400 of 9129 in total
  1. Drug

    Ioxaglic acid

    go.drugbank.com/drugs/DB09313
    ApprovedWithdrawn

    Ioxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. … Ioxaglic acid has a low osmolarity and is associated with fewer side effects compared to older contrast agents [L1883].

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Influenza A virus A/Texas/50/2012 X-223 (H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14392
    Approved

    A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

    Mixtures: AGRIPPAL 2.5 ML IM/SC ENJ.ICIN SUS.ICEREN KUL.HAZIR ENJEKTORSynonyms: Influenza A virus A/Texas/50/2012 X-223 (H3N2) hemagglutinin antigen (propiolactone inactivated)
  3. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.

  4. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension … Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever.

  5. Drug

    MMDA

    go.drugbank.com/drugs/DB01442
    ExperimentalIllicit

    MMDA, or 3-methoxy-4,5-methylenedioxyamphetamine, is a member of the amphetamine drug class with stimulant and psychedelic properties. It also acts as an entheogen and an entactogen. … The effects of MMDA includes feelings of euphoria and warmth, as well as realistic closed-eye visuals.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Etifoxine

    go.drugbank.com/drugs/DB08986
    ApprovedWithdrawn

    It is more effective than lorazepam as an anxiolytic, and has fewer side effects. Etifoxine has been associated with acute liver injury. … Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is used in anxiety disorders and to promote peripheral nerve healing.

  7. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    an alternative to erythromycin treatment [A176170]. … Miocamycin is a macrolide type antimicrobial [A176170]. This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737].

  8. Drug

    Potassium perchlorate

    go.drugbank.com/drugs/DB09418
    ApprovedWithdrawn

    Potassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates. … Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone.

  9. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    [FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

  10. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    [L32033] Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. … [A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow

    Synonyms: 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index